Ballentine Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Ballentine Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,180	Closed	-$288K	–	1081
2025 Q1	$288K	Buy	+2,180	New	+$272K	0.01%	644

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Ballentine Partners's ITCI Position: Q2 2025 in Review

Ballentine Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,180 shares — an estimated $288K sold.

Ballentine Partners first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $288K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Ballentine Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Ballentine Partners sold 2,180 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $288K.
Ballentine Partners first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Ballentine Partners's Intra-Cellular Therapies Inc. position peaked at $288K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Ballentine Partners's 13F filing for Q2 2025, filed 15 Jul 2025.